Because galectin 3 controls retention and endocytosis of cell surface proteins (35), it is possible that abnormal expression and/or regulation of galectin 3 may be associated with AD, and GAL3BP may suppress such pathogenic effects of galectin 3 through direct interaction. This evidence concerns the gene LGALS3 and Alzheimer disease.